

04-12-00

A

04/10/00



Please type a plus sign (+) inside this box ☐

Attorney Docket P1734R1 PATENT

CERTIFICATION UNDER 37 CFR 1.10

EL141796706US: Express Mail Number
Deposit

April 10, 2000: Date of

I hereby certify that this Non-provisional Application Transmittal and the documents referred to as enclosed therein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner of Patents, Washington, D.C. 20231.

Tara E. Faenza



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BOX PATENT APPLICATION
Assistant Commissioner of Patents
Washington, D.C. 20231

NON-PROVISIONAL APPLICATION TRANSMITTAL UNDER 37 CFR 1.53(b)

Transmitted herewith for filing is a non-provisional patent application:

Inventors: Brian Cunningham, San Mateo, California
Abraham de Vos, Oakland, California
Bing Li, Foster City, California

Title: Vascular Endothelial Cell Growth Factor Variants and
Uses Thereof

1. Type of Application
☐ This application is for an original, non-provisional application.
☒ This is a non-provisional application claiming priority to provisional application no. 60/184,235, filed 23 February 2000 and provisional application no. 60/129,788, filed 16 April 1999, the entire disclosures of which are hereby incorporated by reference.
☐ This is a ☐ continuation-in-part ☐ continuation ☐ divisional application claiming priority to application Serial Number , filed , the entire disclosure of which is hereby incorporated by reference.

2. Papers Enclosed Which Are Required For Filing Date Under 37 CFR

1.53(b)

(Non-provisional)
55 pages of specification
2 pages of claims
1 page of abstract
18 sheets of drawings ☒ formal ☐ informal

00546857 04-10-00

3. Declaration or Oath

(for new and CIP applications; also for Cont./Div. where inventor(s) are being added)

☒ An executed declaration of the inventor(s) [] is enclosed ☒ will follow.

(for Cont./Div. where inventorship is the same or inventor(s) being deleted)

☐ A copy of the executed declaration/oath filed in the prior application is enclosed (37 CFR 1.63(d)).

(for Cont./Div. where inventor(s) being deleted)

☐ A signed statement is attached deleting inventor(s) named in the prior application (see 37 CFR 1.63(d)(2) and 1.33(b)).

4. Assignment

(for new and CIP applications)

☒ An Assignment of the invention to GENENTECH, INC. [] is enclosed with attached Recordation Form Cover Sheet ☒ will follow.

(for cont./div.)

☐ The prior application is assigned of record to Genentech, Inc.

5. Amendments (for continuation and divisional applications)

☐ Cancel in this application original claims ____ of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)

☐ A preliminary amendment is enclosed. (Claims added by this amendment have been properly numbered consecutively beginning with the number next following the highest numbered original claim in the prior application.)

Relate Back -- 35 U.S.C. 120 or 35 U.S.C. 119

☒ Amend the specification by inserting before the first line the sentence:

--This is a

☒ non-provisional application
☐ continuation
☐ divisional
☐ continuation-in-part

of co-pending application(s)

☐ Serial No. ____ filed on ____, which application(s) is(are) incorporated herein by reference and to which application(s) priority is claimed under 35 USC §120. --

☐ International Application ____ filed on ____ which designated the U.S., which application(s) is(are) incorporated herein by reference and to which application(s) priority is claimed under 35 USC §120. --

☒ provisional application No. 60/184,235 filed 23 February 2000 and 60/129,788 filed 16 April 1999, the entire disclosures of which are hereby incorporated by reference and to which application(s) priority is claimed under 35 USC §119. --.

00545857 041000

6. Fee Calculation (37 CFR 1.16)

The fee has been calculated as follows:

CLAIMS FOR FEE CALCULATION					
Number Filed		Number Extra		Rate	Basic Fee 37 CFR 1.16(a)
					\$690.00
Total Claims	19	- 20 =	0	X \$18.00	\$0.00
Independent Claims	8	- 3 =	5	X \$78.00	\$390.00
Multiple dependent claim(s), if any				+ \$260.00	
Filing Fee Calculation					\$1,080.00

7. Method of Payment of Fees

The Commissioner is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$1080.00. A duplicate copy of this transmittal is enclosed.

8. Authorization to Charge Additional Fees

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR §1.16 and 1.17, or credit overpayment to Deposit Account No. 07-0630. A duplicate copy of this sheet is enclosed.

9. Additional Papers Enclosed

- ☐ Information Disclosure Statement (37 CFR §1.98) w/ PTO-1449 and citations
- ☐ Submission of "Sequence Listing", computer readable copy, certificate re: sequence listing, and/or amendment pertaining thereto for biological invention containing nucleotide and/or amino acid sequence.
- ☐ A new Power of Attorney or authorization of agent.
- ☒ Other: Return postcard